术前哌柏西利随机临床试验:Rb磷酸化调节与抗增殖反应
哌柏西利组抗增殖反应率显著高于对照组(58% vs 12%,P<0.001),HR阳性/HER2阴性亚组更明显(70% vs 9%,P<0.001),且磷酸化Rb下降与Ki67变化相关。
要点
- 术前短程哌柏西利显著降低早期乳腺癌Ki67,抗增殖反应率58% vs 12%。
- HR阳性/HER2阴性亚组抗增殖反应更显著,70% vs 9%。
- 磷酸化Rb早期下降与增殖抑制相关,或可识别原发耐药。
核心结论
- 术前短程哌柏西利可降低早期乳腺癌患者Ki67。
- Rb磷酸化早期下降与药物对细胞增殖的作用相关,可能识别原发耐药患者。
研究设计与样本
- 随机临床试验,早期乳腺癌患者按3:1随机分配至口服哌柏西利125mg每日14天至术前一天组或不治疗组。
- 共74例分配至哌柏西利组,26例至对照组;93%为HR阳性,8%为HER2阳性。
- 主要终点为第15天Ki67表达自然对数低于1的抗增殖反应。
主要发现
- 哌柏西利组抗增殖反应率显著高于对照组(58% vs 12%,P<0.001),Ki67下降显著更高(P<0.001)。
- HR阳性/HER2阴性亚组中,哌柏西利组抗增殖反应率70% vs 对照组9%(P<0.001)。
- 哌柏西利组磷酸化Rb较基线下降显著高于对照组(P<0.001);治疗患者中Ki67变化与磷酸化Rb变化相关(Spearman r=0.41,P<0.0001)。
- 基因表达分析证实对增殖和细胞周期基因有主要影响;治疗患者中抗增殖反应者的CCNE2表达下降显著多于无反应者(P=0.006)。
关键数值与推荐
- 抗增殖反应定义为第15天Ki67表达自然对数低于1。
- 哌柏西利用法:口服125mg每日一次,连续14天至术前一天。
临床怎么用
- 早期乳腺癌术前短程哌柏西利可抑制增殖,支持其药效学作用。
- 磷酸化Rb早期变化或可作为预测哌柏西利原发耐药的候选生物标志物。
局限性
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The cyclin-dependent kinase 4 (CDK4)/6 inhibitor Palbociclib is a new standard treatment in hormone-receptor positive breast cancer patients. No predictive biomarkers have been identified and no pharmacodynamics has properly been described so far. PATIENTS AND METHODS: Patients with early-breast cancer were randomized 3 : 1 to oral palbociclib 125 mg daily for 14 days until the day before the surgery versus no treatment. Primary objective was antiproliferative response defined as a natural logarithm of Ki67 expression at day 15 below 1. Secondary end points were subgroups analyses and safety. Exploratory analyses included search for predictive biomarkers. Immunostainings (Ki67, RB, pRB, p16, pAKT, pER, pCDK2, CyclinD1), FISH (CCND1) and gene expression (GE) arrays were carried out at baseline and at surgery. In addition, activating PIK3CA and AKT1 mutations were assessed at baseline. RESULTS: 74 patients were allocated to palbociclib and 26 to control. Most patients (93%) were hormone-receptor (HR)-positive, whereas 8% were HER2-positive. Palbociclib led to significantly more antiproliferative responses when compared with control (58% versus 12%, P < 0.001), and to a significantly higher Ki67 decrease (P < 0.001). In the HR-positive/HER2-negative subgroup, this antiproliferative effect was even more marked in the palbociclib arm when compared with control (70% versus 9%, P < 0.001). Palbociclib treatment led also to a significantly higher decrease from baseline in phospho-Rb when compared with control (P < 0.001). Among treated patients, changes in Ki67 correlated with changes in phospho-Rb (Spearman rank r = 0.41, P < 0.0001). GE analyses confirmed a major effect on proliferation and cell cycle genes. Among treated patients, CCNE2 expression was significantly more decreased in antiproliferative responders versus nonresponders (P = 0.006). CONCLUSION: Short-term preoperative palbociclib decreases Ki67 in early-breast cancer patients. Early decrease of Rb phosphorylation correlates with drug's effect on cell proliferation and could potentially identify patients with primary resistance. CLINICAL TRIAL REGISTRATION: NCT02008734.
引用
- Arnedos M, Bayar MA, Cheaib B, et al. Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial. Ann Oncol. 2018. PMID: 29893769. doi:10.1093/annonc/mdy202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。